GlycoMimetics puts off $64M IPO pitch

After downsizing its sought-after haul, GlycoMimetics is postponing its $64 million IPO plans, a sign that the year's investor frenzy over biotech debuts may not be welcoming all comers. Early last month, the Gaithersburg, MD-based company filed to rake in up to $86 million in a first-time offering, scaling it back to $64 million on Oct. 28. Article

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.